{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T00:38:10Z","timestamp":1648859890635},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,12,15]],"date-time":"2013-12-15T00:00:00Z","timestamp":1387065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00347-013-2931-x","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T13:24:19Z","timestamp":1386941059000},"page":"107-112","source":"Crossref","is-referenced-by-count":0,"title":["Pharmakokinetik am vorderen Augenabschnitt"],"prefix":"10.1007","volume":"111","author":[{"given":"K.","family":"Bell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.H.","family":"Grus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,15]]},"reference":[{"key":"2931_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0378-5173(87)90092-5","volume":"38","author":"Ahmed","year":"1987","unstructured":"Ahmed I, Patton TF (1987) Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption. Int J Pharm 38:9\u201321","journal-title":"Int J Pharm"},{"key":"2931_CR2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0168-3659(97)00212-5","volume":"52","author":"Baeyens","year":"1998","unstructured":"Baeyens V, Kaltsatos V, Boisrame B et al (1998) Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. J Control Release 52:215\u2013220","journal-title":"J Control Release"},{"key":"2931_CR3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.all.0000183112.86181.9e","volume":"5","author":"Baudouin","year":"2005","unstructured":"Baudouin C (2005) Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 5:459\u2013463","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2931_CR4","first-page":"3145","volume":"32","author":"Brubaker","year":"1991","unstructured":"Brubaker RF (1991) Flow of aqueous humor in humans [The Friedenwald Lecture]. Invest Ophthalmol Vis Sci 32:3145\u20133166","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2931_CR5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1023\/A:1015813225804","volume":"8","author":"Davies","year":"1991","unstructured":"Davies NM, Farr SJ, Hadgraft J et al (1991) Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions. Pharm Res 8:1039\u20131043","journal-title":"Pharm Res"},{"key":"2931_CR6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjophthalmol-2012-303040","volume":"97","author":"Day","year":"2013","unstructured":"Day DG, Walters TR, Schwartz GF et al (2013) Bimatoprost 0.03\u2009% preservative-free ophthalmic solution versus bimatoprost 0.03\u2009% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol 97:989\u2013993","journal-title":"Br J Ophthalmol"},{"key":"2931_CR7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/1389200043335342","volume":"5","author":"Duvvuri","year":"2004","unstructured":"Duvvuri S, Majumdar S, Mitra AK (2004) Role of metabolism in ocular drug delivery. Curr Drug Metab 5:507\u2013515","journal-title":"Curr Drug Metab"},{"key":"2931_CR8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/OPTH.S40147","volume":"7","author":"Fukuda","year":"2013","unstructured":"Fukuda M, Shibata S, Shibata N et al (2013) Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations. Clin Ophthalmol 7:515\u2013520","journal-title":"Clin Ophthalmol"},{"key":"2931_CR9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","volume":"26","author":"Gaudana","year":"2009","unstructured":"Gaudana R, Jwala J, Boddu SH et al (2009) Recent perspectives in ocular drug delivery. Pharm Res 26:1197\u20131216","journal-title":"Pharm Res"},{"key":"2931_CR10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/jop.1995.11.319","volume":"11","author":"Gebhardt","year":"1995","unstructured":"Gebhardt BM, Kaufman HE (1995) Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine. J Ocul Pharmacol Ther 11:319\u2013327","journal-title":"J Ocul Pharmacol Ther"},{"key":"2931_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jps.2600770104","volume":"77","author":"Grass","year":"1988","unstructured":"Grass GM, Robinson JR (1988) Mechanisms of corneal drug penetration. II: ultrastructural analysis of potential pathways for drug movement. J Pharm Sci 77:15\u201323","journal-title":"J Pharm Sci"},{"key":"2931_CR12","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1167\/iovs.03-0959","volume":"45","author":"Gulsen","year":"2004","unstructured":"Gulsen D, Chauhan A (2004) Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 45:2342\u20132347","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2931_CR13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1023\/A:1016242528222","volume":"12","author":"Gurtler","year":"1995","unstructured":"Gurtler F, Kaltsatos V, Boisrame B et al (1995) Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert. Pharm Res 12:1791\u20131795","journal-title":"Pharm Res"},{"key":"2931_CR14","first-page":"627","volume":"38","author":"Hamalainen","year":"1997","unstructured":"Hamalainen KM, Kananen K, Auriola S et al (1997) Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 38:627\u2013634","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2931_CR15","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1124\/jpet.103.057109","volume":"308","author":"Hatanaka","year":"2004","unstructured":"Hatanaka T, Haramura M, Fei YJ et al (2004) Transport of amino acid-based prodrugs by the Na+- and Cl(\u2212) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther 308:1138\u20131147","journal-title":"J Pharmacol Exp Ther"},{"key":"2931_CR16","doi-asserted-by":"crossref","unstructured":"Hiraoka T, Yamamoto T, Okamoto F et al (2012) Time course of changes in ocular wavefront aberration after administration of eye ointment. Eye (Lond) 26:1310\u20131317","DOI":"10.1038\/eye.2012.142"},{"key":"2931_CR17","first-page":"684","volume":"30","author":"Huang","year":"1989","unstructured":"Huang AJ, Tseng SC, Kenyon KR (1989) Paracellular permeability of corneal and conjunctival epithelia. Invest Ophthalmol Vis Sci 30:684\u2013689","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2931_CR18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jop.1990.6.313","volume":"6","author":"Kao","year":"1990","unstructured":"Kao KD, Lu DW, Chiang CH et al (1990) Corneal and scleral penetration studies of 6-hydroxyethoxy-2-benzothiazole sulfonamide: a topical carbonic anhydrase inhibitor. J Ocul Pharmacol 6:313\u2013320","journal-title":"J Ocul Pharmacol"},{"key":"2931_CR19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0014-4835(73)90070-5","volume":"15","author":"Kaye","year":"1973","unstructured":"Kaye GI, Sibley RC, Hoefle FB (1973) Recent studies on the nature and function of the corneal endothelial barrier. Exp Eye Res 15:585\u2013613","journal-title":"Exp Eye Res"},{"key":"2931_CR20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0168-3659(00)00329-1","volume":"69","author":"Lin","year":"2000","unstructured":"Lin HR, Sung KC (2000) Carbopol\/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 69:379\u2013388","journal-title":"J Control Release"},{"key":"2931_CR21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/1389450043345407","volume":"5","author":"Mainardes","year":"2004","unstructured":"Mainardes RM, Silva LP (2004) Drug delivery systems: past, present, and future. Curr Drug Targets 5:449\u2013455","journal-title":"Curr Drug Targets"},{"key":"2931_CR22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/bjo.2010.198887","volume":"96","author":"Maul","year":"2012","unstructured":"Maul EA, Friedman DS, Quigley HA et al (2012) Impact of eyelid closure on the intraocular pressure lowering effect of prostaglandins: a randomised controlled trial. Br J Ophthalmol 96:250\u2013253","journal-title":"Br J Ophthalmol"},{"key":"2931_CR23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1089\/jop.1996.12.481","volume":"12","author":"Meseguer","year":"1996","unstructured":"Meseguer G, Buri P, Plazonnet B et al (1996) Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther 12:481\u2013488","journal-title":"J Ocul Pharmacol Ther"},{"key":"2931_CR24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijpharm.2012.11.002","volume":"441","author":"Moya-Ortega","year":"2013","unstructured":"Moya-Ortega MD, Alves TF, Alvarez-Lorenzo C et al (2013) Dexamethasone eye drops containing gamma-cyclodextrin-based nanogels. Int J Pharm 441:507\u2013515","journal-title":"Int J Pharm"},{"key":"2931_CR25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/02713680802023104","volume":"33","author":"Mundada","year":"2008","unstructured":"Mundada AS, Shrikhande BK (2008) Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert. Curr Eye Res 33:469\u2013475","journal-title":"Curr Eye Res"},{"key":"2931_CR26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02849799","volume":"20","author":"Mundorf","year":"2003","unstructured":"Mundorf T, Wilcox KA, Ousler GW 3rd et al (2003) Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther 20:329\u2013336","journal-title":"Adv Ther"},{"key":"2931_CR27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF02853166","volume":"18","author":"Noecker","year":"2001","unstructured":"Noecker R (2001) Effects of common ophthalmic preservatives on ocular health. Adv Ther 18:205\u2013215","journal-title":"Adv Ther"},{"key":"2931_CR28","first-page":"2010","volume":"40","author":"Ohta","year":"1999","unstructured":"Ohta K, Wiggert B, Taylor AW et al (1999) Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci 40:2010\u20132018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2931_CR29","first-page":"28","volume":"25","author":"Pham","year":"1999","unstructured":"Pham XT, Huff JW (1999) Cytotoxicity evaluation of multipurpose contact lens solutions using an in vitro test battery. Clao J 25:28\u201335","journal-title":"Clao J"},{"key":"2931_CR30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-4835(77)80009-2","volume":"25","author":"Raviola","year":"1977","unstructured":"Raviola G (1977) The structural basis of the blood-ocular barriers. Exp Eye Res 25(Suppl):27\u201363","journal-title":"Exp Eye Res"},{"key":"2931_CR31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.2042-7158.1982.tb04762.x","volume":"34","author":"Saettone","year":"1982","unstructured":"Saettone MF, Giannaccini B, Teneggi A et al (1982) Vehicle effects on ophthalmic bioavailability: the influence of different polymers on the activity of pilocarpine in rabbit and man. J Pharm Pharmacol 34:464\u2013466","journal-title":"J Pharm Pharmacol"},{"key":"2931_CR32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","volume":"13","author":"Sahoo","year":"2008","unstructured":"Sahoo SK, Dilnawaz F, Krishnakumar S (2008) Nanotechnology in ocular drug delivery. Drug Discov Today 13:144\u2013151","journal-title":"Drug Discov Today"},{"key":"2931_CR33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003088-199018040-00001","volume":"18","author":"Schoenwald","year":"1990","unstructured":"Schoenwald RD (1990) Ocular drug delivery. Pharmacokinetic considerations. Clin Pharmacokinet 18:255\u2013269","journal-title":"Clin Pharmacokinet"},{"key":"2931_CR34","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00417-012-1999-3","volume":"250","author":"Schrage","year":"2012","unstructured":"Schrage N, Frentz M, Spoeler F (2012) The Ex Vivo Eye Irritation Test (EVEIT) in evaluation of artificial tears: Purite-preserved versus unpreserved eye drops. Graefes Arch Clin Exp Ophthalmol 250:1333\u20131340","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2931_CR35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0149-2918(01)80048-5","volume":"23","author":"Shedden","year":"2001","unstructured":"Shedden A, Laurence J, Tipping R (2001) Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther 23:440\u2013450","journal-title":"Clin Ther"},{"key":"2931_CR36","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/jps.21200","volume":"97","author":"Shirasaki","year":"2008","unstructured":"Shirasaki Y (2008) Molecular design for enhancement of ocular penetration. J Pharm Sci 97:2462\u20132496","journal-title":"J Pharm Sci"},{"key":"2931_CR37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2131\/jts.37.639","volume":"37","author":"Tabuchi","year":"2012","unstructured":"Tabuchi N, Hattori M, Shimizu M et al (2012) Evaluation of cytotoxic potential of cored soft contact lenses with adsorbed active ingredients from over-the-counter eye drops. J Toxicol Sci 37:639\u2013643","journal-title":"J Toxicol Sci"},{"key":"2931_CR38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1167\/iovs.02-0499","volume":"44","author":"Talwar","year":"2003","unstructured":"Talwar D, Kulkarni A, Azad R et al (2003) Intraocular ciprofloxacin levels after oral administration in silicone oil-filled eyes. Invest Ophthalmol Vis Sci 44:505\u2013509","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2931_CR39","first-page":"650","volume":"Ophthalmol","author":"Tonjum","year":"1974","unstructured":"Tonjum AM (1974) Permeability of horseradish peroxidase in the rabbit corneal epithelium. Acta Ophthalmol (Copenh) 52:650\u2013658","journal-title":"Acta"},{"key":"2931_CR40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0378-5173(90)90215-P","volume":"61","author":"Urtti","year":"1990","unstructured":"Urtti A, Pipkin JD, Rork G et al (1990) Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits. Int J Pharm 61:241\u2013249","journal-title":"Int J Pharm"},{"key":"2931_CR41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/108076801750295272","volume":"17","author":"Yamada","year":"2001","unstructured":"Yamada Y, Takayanagi R, Tsuchiya K et al (2001) Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther 17:235\u2013248","journal-title":"J Ocul Pharmacol Ther"},{"key":"2931_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9394(14)77404-5","volume":"114","author":"Zimmerman","year":"1992","unstructured":"Zimmerman TJ, Sharir M, Nardin GF et al (1992) Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion. Am J Ophthalmol 114:1\u20137","journal-title":"Am J Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-013-2931-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-013-2931-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-013-2931-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:51:53Z","timestamp":1559051513000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-013-2931-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,15]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["2931"],"URL":"https:\/\/doi.org\/10.1007\/s00347-013-2931-x","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,15]]}}}